KAYOTHERA INC
Small-molecule antagonists targeting retinoid nuclear receptor pathway for therapeutic treatment
- Sector
- Biotech
- Headquarters
- Princeton, NJ
- Founded
- 2019
- Latest Form D
- $4M, Mar 2022
- Total capital
- $5.8M
- Federal grants
- $1.1M
- 3 awards · 2023
- Rank in peer group#429 of 502
- Private capital raised
- $4.8M
- 2 Form D · last Mar 2022
- 55 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 9 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Development of first-in-class antagonists of the retinoid pathway as novel oral therapies for Type 2 Diabetes$338K
- Federal grantHealth and Human S · Phase I · Development of first-in-class antagonists of the retinoid pathway as novel oral therapies for Type 2 Diabetes$338K
- Federal grantHealth and Human S · Phase I · Development of first-in-class antagonists of the retinoid pathway as novel oral immunotherapies for solid cancers$398K
- Private capital raisedForm D · SEC · 2nd filing$4M
- Private capital raisedForm D · SEC · 1st filing$750K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Mark EspositoResearcherExecutive Officer, DirectorLinked by $1.1M in grants as PI
- George F. HeinrichDirectorNamed in SEC Form D filings
- Ian HowesExecutive OfficerNamed in SEC Form D filings
- James M. GolubieskiDirectorNamed in SEC Form D filings
- Kendall MohlerExecutive Officer, DirectorNamed in SEC Form D filings
- KEN MOHLERExecutive Officer, DirectorNamed in SEC Form D filings
Show all 9 people
- SUZANNE RETTENMIERExecutive OfficerNamed in SEC Form D filings
- THONG LEExecutive Officer, DirectorNamed in SEC Form D filings
- Yibin KangDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 9- PendingHeterocyclic Compounds And Uses ThereofUSPTOApplication 19122953
- PendingHeterocyclic Compounds And Uses ThereofUSPTOApplication 17795047
- PendingHeterocyclic Compounds And Uses ThereofUSPTOApplication 63517467
Show all 9 patent records
- Heterocyclic Compounds And Uses ThereofJun 4, 2026 · Application 19122953Pending
- Heterocyclic Compounds And Uses ThereofApr 27, 2023 · Application 17795047Pending
- Heterocyclic Compounds And Uses ThereofApplication 63517467Pending
- Heterocyclic Compounds And Uses ThereofApplication 63418858Pending
- Heterocyclic Compounds And Uses ThereofApplication PCTUS2023077659Pending
- Heterocyclic Compounds And Uses ThereofApplication 63178309Pending
- Heterocyclic Compounds And Uses ThereofApplication PCTUS2021014883Pending
- Heterocyclic Compounds And Uses ThereofApplication 63094741Pending
- Heterocyclic Compounds And Uses ThereofApplication 62965371Pending
Related companies, and why
- Cytoagents, Inc.Similar federal contract value in Biotech · null in contracts
- Aromyx CorpSimilar federal contract value in Biotech · null in contracts
- MODULO BIO, INC.Similar federal contract value in Biotech · null in contracts
- XTRESSE, LLCSimilar federal contract value in Biotech · null in contracts
- Faeth Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Aethon Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .